PSOARING 3:
Remittive Effect

PSOARING 3 was an open-label, LTE study designed to evaluate safety, durability of response, and duration of remittive effect (median time to PGA≥2 from PGA=0) of VTAMA cream in adult patients with plaque psoriasis over 40 weeks.2,26

Remittive effect is continued efficacy and lasting results in adult patients with plaque psoriasis even when off-treatment as demonstrated in the 40-week, open-label, LTE.2,5-7,26

View Study Design


At the end of the 12-week pivotal studies, 763 adult patients (92% of eligible patients) rolled over to the open-label, LTE study26

Significant Results in the Open-Label LTE Study

Disease Clearance and Disease Control of Plaque Psoriasis Demonstrated26-28




40.9% of adult patients (n=312) entered with or achieved complete disease clearance at least once in the open-label LTE study.*26,27




71.2% of adult patients (n=543) entered with or achieved PGA=0 or 1 at least once in the open-label LTE study.†28

*Including patients who entered with PGA=0 (n=79) and patients entering with PGA≥1 who achieved PGA=0 at least once during the open-label LTE study (n=233).26,27
Including patients who entered with PGA=0 or 1 (n=240) and patients entering with PGA≥2 who achieved PGA=0 or 1 at least once during the open-label LTE study (n=303).28